SCHEMBL4364790

SCHEMBL4364790

CCCCCN(C)c1ccc(SNC(=O)NC(=O)c2cc3ccccc3o2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.45
ACKR3 P25106 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRK1 P41145 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
MAPT P10636 4/20 0.39
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPK1 P28482 3/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
HCRTR1 O43613 1/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4363876 0.86 ACKR3 (0.47) ACKR3OPRM1OPRK1TMEM97SIGMAR1
SCHEMBL4364794 0.81 MAPT (0.59) HDAC3MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2866257 0.78 HDAC3 (0.45) HDAC3TAS1R3TAS1R1MAPTNPC1
SCHEMBL2862923 0.77 LMNA (0.57) HDAC3TAS1R3TAS1R1MAPTNPC1
SCHEMBL3426614 0.77 THRB (0.34)
SCHEMBL4518242 0.76 NPC1 (0.43) HDAC3TAS1R3TAS1R1MAPTNPC1
SCHEMBL4365571 0.75 HDAC3 (0.47) HDAC3TAS1R3TAS1R1MAPTNPC1
SCHEMBL3634482 0.71 SMN1; SMN2 (0.51) TAS1R3TAS1R1MAPTNPC1RAB9A
SCHEMBL14096075 0.70 HDAC3 (0.62) HDAC3ACKR3OPRM1OPRK1TMEM97
SCHEMBL4538068 0.70 SMN1; SMN2 (0.49) MAPTNPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
EP-1562895-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2005-08-17 EP claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
WO-2004046095-A1 SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2004-06-03 WO claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7094807-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT HDAC3 378/4885ACKR3 862/4885OPRM1 1742/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 HDAC3 627/4885ACKR3 707/4885OPRM1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.